Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development.

Drug metabolism and pharmacokinetics - 1 Apr 2021

Mochizuki Tatsuki, Mizuno Tadahaya, Maeda Kazuya, Kusuhara Hiroyuki

Abstract excerpt

Drug transporters play important roles in the elimination of various compounds from the blood. Genetic variation and drug-drug interactions underlie the pharmacokinetic differences for the substrates of drug transporters. Some endogenous substrates of drug transporters have emerged as biomarkers to assess differences in drug transporter activity-not only in animals, but also in humans. Metabolomic analysis is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Drug Development

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Membrane Transport Proteins

Share to Pharmaceutical Preparations

Share to Phenotype

Source

Identifiers

PMID: 33461054
DOI: 10.1016/j.dmpk.2020.09.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development.PMID 33461054Read ↗

Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug-drug interactions.Semantic proximity Read ↗

Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effectsSemantic proximity Read ↗

Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter ConsortiumSemantic proximity Read ↗

Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Semantic proximity Read ↗

Circulating Biomarkers Instead of Genotyping to Establish Metabolizer Phenotypes.Semantic proximity Read ↗

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Semantic proximity Read ↗

Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC PerspectiveSemantic proximity Read ↗

Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Semantic proximity Read ↗

[Research on pharmacometabolomics].Semantic proximity Read ↗

Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.Semantic proximity Read ↗

Transporters and drug therapy: implications for drug disposition and disease.Semantic proximity Read ↗

Transporters and drug-drug interactions: important determinants of drug disposition and effects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.